{"entity":{"type":"insider","cik":"0001354397","url":"/insider/0001354397","json_url":"/insider/0001354397.json","name":"Deerfield Special Situations Fund International LTD","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":693,"n_filings":111,"first":"2006-02-24","last":"2013-07-18","span_basis":"filed_date"},"name_variants":[{"name":"Deerfield Special Situations Fund International LTD","source":"filing","n_filings":111,"first_seen":"2006-02-24","last_seen":"2013-07-18"}],"transactions":[{"id":4406308,"accession":"0001193805-13-001292","txn_seq":16,"anchor":"line-16","filing_url":"/filing/0001193805-13-001292","line_url":"/filing/0001193805-13-001292","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Talon Therapeutics, Inc.","issuer_ticker":"TLON.OB","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT CO /NY; DEERFIELD PRIVATE DESIGN FUND L P; Deerfield Special Situations Fund International LTD; Deerfield Mgmt L.P.; Deerfield Private Design International, L.P.; Flynn James E; Deerfield Special Situations Fund, L.P.","owner_display_name":"DEERFIELD MANAGEMENT CO /NY","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27293530.0,"shares_display":"27,293,530","price_per_share":0.0561,"price_display":"0.06","price_state":"stated","total_value":1531167.033,"total_display":"1,531,167.03","total_whole":"1,531,167","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-07-16","filed_date":"2013-07-18","scope":"insider","n_lines":4},{"id":3030993,"accession":"0001193805-12-001149","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193805-12-001149","line_url":"/filing/0001193805-12-001149","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Talon Therapeutics, Inc.","issuer_ticker":"TLON.OB","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Flynn James E; DEERFIELD MANAGEMENT CO /NY; Deerfield Special Situations Fund International LTD; DEERFIELD CAPITAL LP; DEERFIELD PRIVATE DESIGN FUND L P; Deerfield Special Situations Fund, L.P.; Deerfield Private Design International, L.P.","owner_display_name":"Flynn James E","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":540000.0,"shares_display":"540,000","price_per_share":1.22,"price_display":"1.22","price_state":"stated","total_value":658800.0,"total_display":"658,800.00","total_whole":"658,800","shares_owned_after":136849.0,"shares_owned_after_display":"136,849","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-07-05","filed_date":"2012-07-09","scope":"insider","n_lines":4},{"id":9256074,"accession":"0001193805-12-001140","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001193805-12-001140","line_url":"/filing/0001193805-12-001140","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Talon Therapeutics, Inc.","issuer_ticker":"TLON.OB","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD CAPITAL LP; DEERFIELD MANAGEMENT CO /NY; DEERFIELD PRIVATE DESIGN FUND L P; Deerfield Private Design International, L.P.; Deerfield Special Situations Fund International LTD; Deerfield Special Situations Fund, L.P.; Flynn James E","owner_display_name":"DEERFIELD CAPITAL LP","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":550752.0,"shares_display":"550,752","price_per_share":1.33,"price_display":"1.33","price_state":"stated","total_value":732500.16,"total_display":"732,500.16","total_whole":"732,500","shares_owned_after":226684.0,"shares_owned_after_display":"226,684","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-07-03","filed_date":"2012-07-06","scope":"insider","n_lines":4},{"id":3494262,"accession":"0001193805-12-001125","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001193805-12-001125","line_url":"/filing/0001193805-12-001125","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Talon Therapeutics, Inc.","issuer_ticker":"TLON.OB","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Flynn James E; DEERFIELD MANAGEMENT CO /NY; DEERFIELD PRIVATE DESIGN FUND L P; Deerfield Special Situations Fund, L.P.; DEERFIELD CAPITAL LP; Deerfield Private Design International, L.P.; Deerfield Special Situations Fund International LTD","owner_display_name":"Flynn James E","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":550752.0,"shares_display":"550,752","price_per_share":1.33,"price_display":"1.33","price_state":"stated","total_value":732500.16,"total_display":"732,500.16","total_whole":"732,500","shares_owned_after":299811.0,"shares_owned_after_display":"299,811","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-07-03","filed_date":"2012-07-03","scope":"insider","n_lines":4},{"id":9256073,"accession":"0001193805-12-001140","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193805-12-001140","line_url":"/filing/0001193805-12-001140","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Talon Therapeutics, Inc.","issuer_ticker":"TLON.OB","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD CAPITAL LP; DEERFIELD MANAGEMENT CO /NY; DEERFIELD PRIVATE DESIGN FUND L P; Deerfield Private Design International, L.P.; Deerfield Special Situations Fund International LTD; Deerfield Special Situations Fund, L.P.; Flynn James E","owner_display_name":"DEERFIELD CAPITAL LP","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":166527.0,"shares_display":"166,527","price_per_share":1.2,"price_display":"1.20","price_state":"stated","total_value":199832.4,"total_display":"199,832.40","total_whole":"199,832","shares_owned_after":598181.0,"shares_owned_after_display":"598,181","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-07-02","filed_date":"2012-07-06","scope":"insider","n_lines":4},{"id":3494255,"accession":"0001193805-12-001125","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001193805-12-001125","line_url":"/filing/0001193805-12-001125","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Talon Therapeutics, Inc.","issuer_ticker":"TLON.OB","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Flynn James E; DEERFIELD MANAGEMENT CO /NY; DEERFIELD PRIVATE DESIGN FUND L P; Deerfield Special Situations Fund, L.P.; DEERFIELD CAPITAL LP; Deerfield Private Design International, L.P.; Deerfield Special Situations Fund International LTD","owner_display_name":"Flynn James E","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":166527.0,"shares_display":"166,527","price_per_share":1.2,"price_display":"1.20","price_state":"stated","total_value":199832.4,"total_display":"199,832.40","total_whole":"199,832","shares_owned_after":582991.0,"shares_owned_after_display":"582,991","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-07-02","filed_date":"2012-07-03","scope":"insider","n_lines":4},{"id":3494247,"accession":"0001193805-12-001125","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193805-12-001125","line_url":"/filing/0001193805-12-001125","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Talon Therapeutics, Inc.","issuer_ticker":"TLON.OB","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Flynn James E; DEERFIELD MANAGEMENT CO /NY; DEERFIELD PRIVATE DESIGN FUND L P; Deerfield Special Situations Fund, L.P.; DEERFIELD CAPITAL LP; Deerfield Private Design International, L.P.; Deerfield Special Situations Fund International LTD","owner_display_name":"Flynn James E","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":194635.0,"shares_display":"194,635","price_per_share":1.14,"price_display":"1.14","price_state":"stated","total_value":221883.9,"total_display":"221,883.90","total_whole":"221,884","shares_owned_after":668614.0,"shares_owned_after_display":"668,614","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-06-29","filed_date":"2012-07-03","scope":"insider","n_lines":4},{"id":2111193,"accession":"0001193805-12-001090","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001193805-12-001090","line_url":"/filing/0001193805-12-001090","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Talon Therapeutics, Inc.","issuer_ticker":"TLON.OB","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Flynn James E; DEERFIELD MANAGEMENT CO /NY; Deerfield Private Design International, L.P.; DEERFIELD PRIVATE DESIGN FUND L P; DEERFIELD CAPITAL LP; Deerfield Special Situations Fund, L.P.; Deerfield Special Situations Fund International LTD","owner_display_name":"Flynn James E","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":219800.0,"shares_display":"219,800","price_per_share":1.07,"price_display":"1.07","price_state":"stated","total_value":235186.0,"total_display":"235,186.00","total_whole":"235,186","shares_owned_after":750935.0,"shares_owned_after_display":"750,935","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-06-28","filed_date":"2012-06-28","scope":"insider","n_lines":4},{"id":2111144,"accession":"0001193805-12-001090","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001193805-12-001090","line_url":"/filing/0001193805-12-001090","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Talon Therapeutics, Inc.","issuer_ticker":"TLON.OB","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Flynn James E; DEERFIELD MANAGEMENT CO /NY; Deerfield Private Design International, L.P.; DEERFIELD PRIVATE DESIGN FUND L P; DEERFIELD CAPITAL LP; Deerfield Special Situations Fund, L.P.; Deerfield Special Situations Fund International LTD","owner_display_name":"Flynn James E","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":116256.0,"shares_display":"116,256","price_per_share":1.0,"price_display":"1.00","price_state":"stated","total_value":116256.0,"total_display":"116,256.00","total_whole":"116,256","shares_owned_after":843899.0,"shares_owned_after_display":"843,899","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-06-27","filed_date":"2012-06-28","scope":"insider","n_lines":4},{"id":2111135,"accession":"0001193805-12-001090","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193805-12-001090","line_url":"/filing/0001193805-12-001090","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Talon Therapeutics, Inc.","issuer_ticker":"TLON.OB","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Flynn James E; DEERFIELD MANAGEMENT CO /NY; Deerfield Private Design International, L.P.; DEERFIELD PRIVATE DESIGN FUND L P; DEERFIELD CAPITAL LP; Deerfield Special Situations Fund, L.P.; Deerfield Special Situations Fund International LTD","owner_display_name":"Flynn James E","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":62317.0,"shares_display":"62,317","price_per_share":0.98,"price_display":"0.98","price_state":"stated","total_value":61070.66,"total_display":"61,070.66","total_whole":"61,071","shares_owned_after":893069.0,"shares_owned_after_display":"893,069","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-06-26","filed_date":"2012-06-28","scope":"insider","n_lines":4},{"id":3551722,"accession":"0001193805-12-000848","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001193805-12-000848","line_url":"/filing/0001193805-12-000848","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Talon Therapeutics, Inc.","issuer_ticker":"TLON.OB","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design International, L.P.; Deerfield Special Situations Fund, L.P.; DEERFIELD CAPITAL LP; DEERFIELD PRIVATE DESIGN FUND L P; DEERFIELD MANAGEMENT CO /NY; Deerfield Special Situations Fund International LTD; Flynn James E","owner_display_name":"Deerfield Private Design International, L.P.","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":231100.0,"shares_display":"231,100","price_per_share":0.9871830376460407,"price_display":"0.99","price_state":"stated","total_value":228138.0,"total_display":"228,138.00","total_whole":"228,138","shares_owned_after":946926.0,"shares_owned_after_display":"946,926","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-05-03","filed_date":"2012-05-07","scope":"insider","n_lines":8},{"id":3420658,"accession":"0001193805-12-000538","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193805-12-000538","line_url":"/filing/0001193805-12-000538#line-4","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Talon Therapeutics, Inc.","issuer_ticker":"TLON.OB","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design International, L.P.; DEERFIELD MANAGEMENT CO /NY; Deerfield Special Situations Fund International LTD; DEERFIELD PRIVATE DESIGN FUND L P; Flynn James E; Deerfield Special Situations Fund, L.P.; DEERFIELD CAPITAL LP","owner_display_name":"Deerfield Private Design International, L.P.","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":48600.0,"shares_display":"48,600","price_per_share":1.05,"price_display":"1.05","price_state":"stated","total_value":51030.0,"total_display":"51,030.00","total_whole":"51,030","shares_owned_after":1017110.0,"shares_owned_after_display":"1,017,110","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-03-21","filed_date":"2012-03-23","scope":"insider"},{"id":3420657,"accession":"0001193805-12-000538","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193805-12-000538","line_url":"/filing/0001193805-12-000538#line-3","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Talon Therapeutics, Inc.","issuer_ticker":"TLON.OB","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design International, L.P.; DEERFIELD MANAGEMENT CO /NY; Deerfield Special Situations Fund International LTD; DEERFIELD PRIVATE DESIGN FUND L P; Flynn James E; Deerfield Special Situations Fund, L.P.; DEERFIELD CAPITAL LP","owner_display_name":"Deerfield Private Design International, L.P.","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30226.0,"shares_display":"30,226","price_per_share":1.05,"price_display":"1.05","price_state":"stated","total_value":31737.3,"total_display":"31,737.30","total_whole":"31,737","shares_owned_after":631355.0,"shares_owned_after_display":"631,355","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-03-21","filed_date":"2012-03-23","scope":"insider"}],"collapsed":true,"next_cursor":"2012-03-21|3420657","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001140028","name":"Talon Therapeutics, Inc.","url":"/issuer/0001140028","role":"Ten percent owner, Other","n_filings":22,"first_seen":"2011-05-19","last_seen":"2013-07-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001034842","name":"RIGEL PHARMACEUTICALS INC","url":"/issuer/0001034842","role":"Ten percent owner, Other","n_filings":2,"first_seen":"2010-11-05","last_seen":"2011-06-07"},{"type":"issuer","type_label":"ISSUER","cik":"0000930553","name":"ISTA PHARMACEUTICALS INC","url":"/issuer/0000930553","role":"Ten percent owner, Other","n_filings":9,"first_seen":"2006-05-11","last_seen":"2011-05-06"},{"type":"issuer","type_label":"ISSUER","cik":"0000879993","name":"DUSA PHARMACEUTICALS INC","url":"/issuer/0000879993","role":"Ten percent owner, Other","n_filings":5,"first_seen":"2009-02-25","last_seen":"2011-03-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001289850","name":"NeuroMetrix, Inc.","url":"/issuer/0001289850","role":"Ten percent owner, Other","n_filings":8,"first_seen":"2009-09-11","last_seen":"2010-12-14"},{"type":"issuer","type_label":"ISSUER","cik":"0000887497","name":"HI TECH PHARMACAL CO INC","url":"/issuer/0000887497","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2010-12-13","last_seen":"2010-12-13"},{"type":"issuer","type_label":"ISSUER","cik":"0000357097","name":"Fibrocell Science, Inc.","url":"/issuer/0000357097","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2010-08-18","last_seen":"2010-08-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001333170","name":"NxStage Medical, Inc.","url":"/issuer/0001333170","role":"Ten percent owner","n_filings":10,"first_seen":"2009-06-19","last_seen":"2009-12-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001385830","name":"NeurogesX Inc","url":"/issuer/0001385830","role":"Ten percent owner","n_filings":5,"first_seen":"2009-06-25","last_seen":"2009-07-15"},{"type":"issuer","type_label":"ISSUER","cik":"0000927829","name":"NITROMED INC","url":"/issuer/0000927829","role":"Ten percent owner, Other","n_filings":16,"first_seen":"2008-05-06","last_seen":"2009-04-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001121439","name":"EMAGEON INC","url":"/issuer/0001121439","role":"Ten percent owner","n_filings":1,"first_seen":"2009-03-02","last_seen":"2009-03-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001130166","name":"Cyclacel Pharmaceuticals, Inc.","url":"/issuer/0001130166","role":"Ten percent owner","n_filings":2,"first_seen":"2008-11-14","last_seen":"2008-11-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001029142","name":"DYNAVAX TECHNOLOGIES CORP","url":"/issuer/0001029142","role":"Ten percent owner, Other","n_filings":11,"first_seen":"2006-03-07","last_seen":"2008-10-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001128495","name":"ANADYS PHARMACEUTICALS INC","url":"/issuer/0001128495","role":"Ten percent owner","n_filings":1,"first_seen":"2008-10-21","last_seen":"2008-10-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001003929","name":"VIA Pharmaceuticals, Inc.","url":"/issuer/0001003929","role":"Ten percent owner, Other","n_filings":5,"first_seen":"2007-10-19","last_seen":"2007-11-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001120438","name":"THIRD WAVE TECHNOLOGIES INC /WI","url":"/issuer/0001120438","role":"Ten percent owner, Other","n_filings":4,"first_seen":"2007-04-20","last_seen":"2007-05-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001040416","name":"INSPIRE PHARMACEUTICALS INC","url":"/issuer/0001040416","role":"Ten percent owner, Other","n_filings":7,"first_seen":"2006-02-24","last_seen":"2007-05-02"},{"type":"issuer","type_label":"ISSUER","cik":"0000878088","name":"PAR PHARMACEUTICAL COMPANIES, INC.","url":"/issuer/0000878088","role":"Ten percent owner","n_filings":1,"first_seen":"2007-02-01","last_seen":"2007-02-01"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001354397","retrieved_at":"2026-08-22T08:47:43+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}